Nebicur (Nebivolol Hydrochloride)

• Nebivolol Hydrochloride is a selective β1‑adrenergic blocker indicated for conditions that involve elevated blood pressure or impaired cardiac function.
• Hypertension: lowers systolic and diastolic pressure by reducing cardiac output and peripheral vascular resistance.
• Heart failure: improves left‑ventricular ejection fraction and reduces symptoms in patients with reduced‑ejection‑fraction heart failure.

• Nebivolol Hydrochloride selectively antagonises β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which further contributes to blood‑pressure reduction without significant β2‑receptor blockade.

Nebivolol Hydrochloride may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or general tiredness.
• Nausea or mild gastrointestinal upset.
• Nasal congestion or rhinorrhoea.

Serious or Rare Side Effects

• Severe bradycardia or heart block.
• Marked hypotension leading to syncope.
• Bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, angioedema, or anaphylaxis.
• Hepatic enzyme elevations or liver injury.
• Worsening heart failure symptoms.

• Before initiating Nebivolol Hydrochloride, clinicians should consider several safety aspects.
• Monitor blood pressure: verify adequate control and avoid excessive hypotension.
• Assess cardiac function: evaluate baseline heart rate and conduction abnormalities.
• Use caution in asthma/COPD: β‑blockade may precipitate bronchospasm.
• Review concomitant beta‑blockers: avoid additive negative‑chronotropic effects.
• Adjust in renal/hepatic impairment: dose may need modification in severe dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol Hydrochloride can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other beta‑blockers: additive bradycardia and AV‑node depression.
• Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): increased risk of heart block.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): may raise nebivolol plasma levels.
• Clonidine abrupt withdrawal: can cause rebound hypertension.
• Antihypertensive agents that cause profound vasodilation (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance orthostatic hypotension.
• Antidiabetic drugs: beta‑blockade can mask hypoglycaemia symptoms.
• NSAIDs: may reduce antihypertensive efficacy.
• Antidepressants (serotonergic agents): monitor for additive dizziness.
• Digoxin: monitor for bradycardia when combined.